Daratumumab and TCZ in Late Antibody-Mediated Rejection Treatment
The following is a summary of “Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodies: a pilot study,” published in the January 2025...